Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Christine Katlama

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Wirden Marc; Simon Anne; Schneider Luminita; Tubiana Roland; Malet Isabelle; Ait-Mohand Hocine; Peytavin Gilles; Katlama Christine; Calvez Vincent; Marcelin Anne-Genevieve
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
Katlama Christine; Haubrich Richard; Lalezari Jacob; Lazzarin Adriano; Madruga José V; Molina Jean-Michel; Schechter Mauro; Peeters Monika; Picchio Gaston; Vingerhoets Johan; Woodfall Brian; De Smedt Goedele;
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
De Castro Nathalie; Braun Joséphine; Charreau Isabelle; Pialoux Gilles; Cotte Laurent; Katlama Christine; Raffi François; Weiss Laurence; Meynard Jean-Luc; Yazdanpanah Yazdan; Delaugerre Constance; Madelaine-Chambrin Isabelle; Aboulker Jean-Pierre; Molina Jean-Michel;
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Christine Katlama (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Wirden Marc; Simon Anne; Schneider Luminita; Tubiana Roland; Malet Isabelle; Ait-Mohand Hocine; Peytavin Gilles; Katlama Christine; Calvez Vincent; Marcelin Anne-Genevieve
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
The Journal of antimicrobial chemotherapy 2009;64(5):1087-90.
2009: Katlama Christine; Haubrich Richard; Lalezari Jacob; Lazzarin Adriano; Madruga José V; Molina Jean-Michel; Schechter Mauro; Peeters Monika; Picchio Gaston; Vingerhoets Johan; Woodfall Brian; De Smedt Goedele;
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
AIDS (London, England) 2009;23(17):2289-300.
2009: De Castro Nathalie; Braun Joséphine; Charreau Isabelle; Pialoux Gilles; Cotte Laurent; Katlama Christine; Raffi François; Weiss Laurence; Meynard Jean-Luc; Yazdanpanah Yazdan; Delaugerre Constance; Madelaine-Chambrin Isabelle; Aboulker Jean-Pierre; Molina Jean-Michel;
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(8):1259-67.
2009: Mounier Nicolas; Katlama Christine; Costagliola Dominique; Chichmanian Rose-Marie; Spano Jean-Philippe
Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.
Critical reviews in oncology/hematology 2009;72(1):10-20.
2009: Cozzi-Lepri Alessandro; Phillips Andrew N; Martinez-Picado Javier; Monforte Antonella d'Arminio; Katlama Christine; Eg Hansen Ann-Brit; Horban Andrzej; Bruun Johann; Clotet Bonaventura; Lundgren Jens D;
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
The Journal of infectious diseases 2009;200(5):687-97.
2009: Soulié Cathia; Assoumou Lambert; Ghosn Jade; Duvivier Claudine; Peytavin Gilles; Ait-Arkoub Zaina; Molina Jean-Michel; Costagliola Dominique; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
AIDS (London, England) 2009;23(12):1605-8.
2009: Landman Roland; Capitant Catherine; Descamps Diane; Chazallon Corine; Peytavin Gilles; Katlama Christine; Pialoux Gilles; Bentata Michelle; Brun-Vézinet Francoise; Aboulker Jean-Pierre; Yéni Patrick;
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
The Journal of antimicrobial chemotherapy 2009;64(1):118-25.
2009: Girard Pierre-Marie; Cabié André; Michelet Christian; Verdon Renaud; Katlama Christine; Mercié Patrick; Morand-Joubert Laurence; Pétour Pascal; Monchecourt Françoise; Chêne Geneviève; Trylesinski Aldo;
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
The Journal of antimicrobial chemotherapy 2009;64(1):126-34.
2009: Murphy Robert L; Autran Brigitte; Katlama Christine; Brucker Gilles; Debre Patrice; Calvez Vincent; Clotet Bonaventura; Clumeck Nathan; Costagliola Dominique; Deeks Steven G; Dorrell Lucy; Gatell Jose; Haase Ashley; Klein Michel; Lazzarin Adriano; McMichael Andrew J; Papagno Laura; Schacker Timothy W; Wain-Hobson Simon; Walker Bruce D; Youle Michael
A step ahead on the HIV collaboratory.
Science (New York, N.Y.) 2009;324(5932):1264-5.
2009: Puissant-Lubrano Bénédicte; Combadière Béhazine; Duffy Darragh; Wincker Norma; Frachette Marie-Joelle; Ait-Mohand Hocine; Verrier Bernard; Katlama Christine; Autran Brigitte
Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients.
Vaccine 2009;27(27):3576-83.
2009: Soulié Cathia; Tubiana Roland; Simon Anne; Lambert-Niclot Sidonie; Malet Isabelle; Canestri Ana; Brunet Christel; Murphy Robert; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):60-4.
2009: Wirden M; Tubiana R; Marguet F; Leroy I; Simon A; Bonmarchand M; Ait-Arkoub Z; Murphy R; Marcelin A G; Katlama C; Calvez V
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.
Journal of clinical microbiology 2009;47(5):1543-5.
2009: Katlama Christine; Murphy Robert
Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.
Therapeutics and clinical risk management 2009;5(2):331-40.
2009: Duvivier Claudine; Kolta Sami; Assoumou Lambert; Ghosn Jade; Rozenberg Sylvie; Murphy Robert L; Katlama Christine; Costagliola Dominique;
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
AIDS (London, England) 2009;23(7):817-24.
2009: Malet Isabelle; Delelis Olivier; Soulie Cathia; Wirden Marc; Tchertanov Luba; Mottaz Philippe; Peytavin Gilles; Katlama Christine; Mouscadet Jean-François; Calvez Vincent; Marcelin Anne-Genevieve
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 2009;63(4):795-804.
2009: Descamps Diane; Lambert-Niclot Sidonie; Marcelin Anne-Geneviève; Peytavin Gilles; Roquebert Bénédicte; Katlama Christine; Yeni Patrick; Felices Mathieu; Calvez Vincent; Brun-Vézinet Françoise
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
The Journal of antimicrobial chemotherapy 2009;63(3):585-92.
2009: Ingiliz Patrick; Valantin Marc-Antoine; Duvivier Claudine; Medja Fadia; Dominguez Stephanie; Charlotte Frédéric; Tubiana Roland; Poynard Thierry; Katlama Christine; Lombès Anne; Benhamou Yves
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.
Hepatology (Baltimore, Md.) 2009;49(2):436-42.
2009: Peytavin Gilles; Calvez Vincent; Katlama Christine
[CCR5 antagonists: a new class of antiretrovirals]
Thérapie 2009;64(1):9-16.
2009: Wirden Marc; Lambert-Niclot Sidonie; Marcelin Anne-Genevieve; Schneider Luminita; Ait-Mohand Hocine; Brunet Christel; Angleraud Francis; Amard Sylvain; Katlama Christine; Calvez Vincent
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
AIDS (London, England) 2009;23(1):95-9.
2009: Maïga Almoustapha-Issiaka; Malet Isabelle; Soulie Cathia; Derache Anne; Koita Victoria; Amellal Bahia; Tchertanov Luba; Delelis Olivier; Morand-Joubert Laurence; Mouscadet Jean-François; Murphy Robert; Cissé Mamadou; Katlama Christine; Calvez Vincent; Marcelin Anne-Genevieve
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
Antiviral therapy 2009;14(1):123-9.
2009: Horne Robert; Kovacs Colin; Katlama Christine; Clotet Bonaventura; Fumaz Carmina R; Youle Michael; Kulasegaram Ranjababu; Fisher Martin; Cohen Calvin; Slim Jihad; Shalit Peter; Cooper Vanessa; Tsoukas Christos
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
AIDS research and therapy 2009;6():2.
2008: Marcelin Anne-Geneviève; Flandre Philippe; Molina Jean-Michel; Katlama Christine; Yeni Patrick; Raffi Francois; Antoun Zeina; Ait-Khaled Mounir; Calvez Vincent
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Antimicrobial agents and chemotherapy 2008;52(12):4251-7.
2008: Calmy Alexandra; Pizzocolo Cecilia; Pizarro Louis; Brücker Gilles; Murphy Robert; Katlama Christine;
The marriage of science and optimized HIV care in resource-limited settings.
AIDS (London, England) 2008;22(17):2227-30.
2008: Soriano Vincent; Mocroft Amanda; Rockstroh Juergen; Ledergerber Bruno; Knysz Brygida; Chaplinskas Saulius; Peters Lars; Karlsson Anders; Katlama Christine; Toro Carlos; Kupfer Bernd; Vogel Martin; Lundgren Jens;
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe.
The Journal of infectious diseases 2008;198(9):1337-44.
2008: Lambert-Niclot Sidonie; Flandre Philippe; Malet Isabelle; Canestri Ana; Soulié Cathia; Tubiana Roland; Brunet Christel; Wirden Marc; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
The Journal of antimicrobial chemotherapy 2008;62(5):905-8.
2008: Soulié Cathia; Malet Isabelle; Lambert-Niclot Sidonie; Tubiana Roland; Thévenin Monique; Simon Anne; Murphy Robert; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
AIDS (London, England) 2008;22(16):2212-4.
2008: Amellal B; Murphy R; Maiga A; Brucker G; Katlama C; Calvez V; Marcelin A G
Stability of HIV RNA in plasma specimens stored at different temperatures.
HIV medicine 2008;9(9):790-3.
2008: Ait-Mohand H; Bonmarchand M; Guiguet M; Slama L; Marguet F; Behin A; Amellal B; Bennai Y; Peytavin G; Calvez V; Pialoux G; Murphy R; Katlama C
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
HIV medicine 2008;9(9):738-46.
2008: Duvivier Claudine; Ghosn Jade; Assoumou Lambert; Soulié Cathia; Peytavin Gilles; Calvez Vincent; Génin Michèle Algarté; Molina Jean-Michel; Bouchaud Olivier; Katlama Christine; Costagliola Dominique;
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
The Journal of antimicrobial chemotherapy 2008;62(4):797-808.
2008: Valantin M A; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
HIV medicine 2008;9(8):625-35.
2008: Spano Jean-Philippe; Costagliola Dominique; Katlama Christine; Mounier Nicolas; Oksenhendler Eric; Khayat David
AIDS-related malignancies: state of the art and therapeutic challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4834-42.
2008: Derache Anne; Maiga Almoustapha-Issiaka; Traore Ousmane; Akonde Alain; Cisse Mamadou; Jarrousse Bernard; Koita Victoria; Diarra Bah; Carcelain Guislaine; Barin Francis; Pizzocolo Cecilia; Pizarro Louis; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
The Journal of antimicrobial chemotherapy 2008;62(3):456-63.
2008: Cooper David A; Steigbigel Roy T; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Teppler Hedy; Nguyen Bach-Yen;
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Steigbigel Roy T; Cooper David A; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Nguyen Bach-Yen; Teppler Hedy;
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: Autran Brigitte; Murphy Robert L; Costagliola Dominique; Tubiana Roland; Clotet Bonaventura; Gatell Jose; Staszewski Schlomo; Wincker Norma; Assoumou Lambert; El-Habib Raphaelle; Calvez Vincent; Walker Bruce; Katlama Christine;
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
AIDS (London, England) 2008;22(11):1313-22.
2008: Bannister Wendy P; Cozzi-Lepri Alessandro; Clotet Bonaventura; Mocroft Amanda; Kjaer Jesper; Reiss Peter; von Wyl Viktor; Lazzarin Adriano; Katlama Christine; Phillips Andrew N; Ruiz Lidia; Lundgren Jens D;
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Journal of acquired immune deficiency syndromes (1999) 2008;48(3):324-33.
2008: Malet Isabelle; Soulie Cathia; Tchertanov Luba; Derache Anne; Amellal Bahia; Traore Ousmane; Simon Anne; Katlama Christine; Mouscadet Jean-François; Calvez Vincent; Marcelin Anne-Geneviève
Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases.
Journal of medical virology 2008;80(5):754-61.
2008: Ghosn Jade; De Montgolfier Ines; Cornélie Chantal; Dominguez Stéphanie; Pérot Claire; Peytavin Gilles; Marcelin Anne-Geneviève; Pauchard Michèle; Ouagari Zineb; Bonmarchand Manuela; Agher Rachid; Calvez Vincent; Bricaire François; Dommergues Marc; Katlama Christine; Tubiana Roland
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.
Antimicrobial agents and chemotherapy 2008;52(4):1542-4.
2008: Malet Isabelle; Delelis Olivier; Valantin Marc-Antoine; Montes Brigitte; Soulie Cathia; Wirden Marc; Tchertanov Luba; Peytavin Gilles; Reynes Jacques; Mouscadet Jean-François; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrobial agents and chemotherapy 2008;52(4):1351-8.
2008: Walmsley Sharon L; Katlama Christine; Lazzarin Adriano; Arestéh Keikawus; Pierone Gerald; Blick Gary; Johnson Margaret; Meier Ulrich; MacGregor Thomas R; Leith Johnathan G
Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Journal of acquired immune deficiency syndromes (1999) 2008;47(4):429-40.
2008: Chidiac C; Katlama C; Yeni P
[Maraviroc: clinical trials results]
Médecine et maladies infectieuses 2008;38 Suppl 1():S17-23.
2008: Hill Andrew; Hirschel Bernard; Katlama Christine
The Monark trial: where now for boosted protease inhibitor monotherapy?
AIDS (London, England) 2008;22(6):777-9.
2008: Angus Brian; Lampe Fiona; Tambussi Guiseppe; Duvivier Claudine; Katlama Christine; Youle Mike; Williams Ian; Clotet Bonaventura; Fisher Martin; Post Frank A; Babiker Abdul; Phillips Andrew;
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
AIDS (London, England) 2008;22(6):737-40.
2008: Izzedine Hassane; Brocheriou Isabelle; Valantin Marc-Antoine; Camous Laurent; Bourry Edward; Baumelou Alain; Deray Gilbert; Katlama Christine
A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome.
Nature clinical practice. Nephrology 2008;4(2):110-4.
2008: Vogt Annika; Mahé Brice; Costagliola Dominique; Bonduelle Olivia; Hadam Sabrina; Schaefer Gregor; Schaefer Hans; Katlama Christine; Sterry Wolfram; Autran Brigitte; Blume-Peytavi Ulrike; Combadiere Béhazine
Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(3):1482-9.
2008: Lambert-Niclot Sidonie; Flandre Philippe; Canestri Ana; Peytavin Gilles; Blanc Christine; Agher Rachid; Soulié Cathia; Wirden Marc; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Antimicrobial agents and chemotherapy 2008;52(2):491-6.
2008: Mocroft A; Horban A; Clotet B; d'Arminio Monforte A; Bogner J R; Aldins P; Staub T; Antunes F; Katlama C; Lundgren J D;
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
HIV medicine 2008;9(1):41-6.
2008: Soulié C; Derache A; Aimé C; Marcelin A-G; Carcelain G; Simon A; Katlama C; Calvez V
Comparison of two genotypic algorithms to determine HIV-1 tropism.
HIV medicine 2008;9(1):1-5.
2008: Ingiliz Patrick; Valantin Marc-Antoine; Thibault Vincent; Duvivier Claudine; Dominguez Stephanie; Katlama Christine; Poynard Thierry; Benhamou Yves
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Antiviral therapy 2008;13(7):895-900.
2008: Podlekareva Daria; Mocroft Amanda; Kirk Ole; Reiss Peter; Aldins Pauls; Katlama Christine; Kovari Helen; Stellbrink Hans-Juergen; D'Arminio Monforte Antonella; Lundgren Jens D;
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
Scandinavian journal of infectious diseases 2008;40(11-12):908-13.
2007: Marcelin Anne-Geneviève; Jarrousse Bernard; Derache Anne; Ba Madina; Dakouo Marie-Léa; Doumbia Alioune; Haidara Ibrahima; Maïga Almoustapha; Carcelain Guislaine; Peytavin Gilles; Katlama Christine; Calvez Vincent
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
AIDS (London, England) 2007;21(17):2341-3.
2007: Lesprit Philippe; Pédrono Gaëlle; Molina Jean-Michel; Goujard Cécile; Girard Pierre-Marie; Sarrazin Nathalie; Katlama Christine; Yéni Patrick; Morineau Pascale; Delfraissy Jean-François; Chêne Geneviève; Lévy Yves;
Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
AIDS (London, England) 2007;21(18):2425-34.
2007: Soulié Cathia; Marcelin Anne-Geneviève; Ghosn Jade; Amellal Bahia; Assoumou Lambert; Lambert Sidonie; Duvivier Claudine; Costagliola Dominique; Katlama Christine; Calvez Vincent
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
AIDS (London, England) 2007;21(16):2243-5.
2007: Izzedine Hassane; Valantin Marc Antoine; Daudon Michel; Mohand Hocine Ait; Caby Fabienne; Katlama Christine
Efavirenz urolithiasis.
AIDS (London, England) 2007;21(14):1992.
2007: Lewden Charlotte; Chene Genevieve; Morlat Philippe; Raffi Francois; Dupon Michel; Dellamonica Pierre; Pellegrin Jean-Luc; Katlama Christine; Dabis Francois; Leport Catherine;
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population.
Journal of acquired immune deficiency syndromes (1999) 2007;46(1):72-7.
2007: Molina Jean-Michel; Cohen Calvin; Katlama Christine; Grinsztejn Beatriz; Timerman Artur; Pedro Rogerio de Jesus; Vangeneugden Tony; Miralles Diego; Meyer Sandra De; Parys Wim; Lefebvre Eric;
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Journal of acquired immune deficiency syndromes (1999) 2007;46(1):24-31.
2007: Reynes Jacques; Arastéh Keikawus; Clotet Bonaventura; Cohen Calvin; Cooper David A; Delfraissy Jean-François; Eron Joseph J; Henry Keith; Katlama Christine; Kuritzkes Daniel R; Lalezari Jacob P; Lange Joep; Lazzarin Adriano; Montaner Julio S G; Nelson Mark; O' Hearn Mary; Stellbrink Hans-Jürgen; Trottier Benoit; Walmsley Sharon L; Buss Neil E; Demasi Ralph; Chung Jain; Donatacci Lucille; Guimaraes Denise; Rowell Lucy; Valentine Adeline; Wilkinson Martin; Salgo Miklos P
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Canestri Ana; Cisse Mamadou; Marcelin Anne-Geneviève; Peytavin Gilles; Traore Emmanuel; Assoumou Lambert; Traore Ousmane; Koita Victoria; Diallo Fodie; Sangare Awa Thiero; Sidibé Mayrama Koita; Calvez Vincent; Sylla Aliou; Katlama Christine; Tubiana Roland
Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
Journal of acquired immune deficiency syndromes (1999) 2007;45(4):477-9.
2007: Podzamczer Daniel; King Martin S; Klein Cheri E; Flexner Charles; Katlama Christine; Havlir Diane V; Letendre Scott L; Eron Joseph J; Brun Scott C; Bernstein Barry
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
HIV clinical trials 2007;8(4):193-204.
2007: Lazzarin Adriano; Campbell Thomas; Clotet Bonaventura; Johnson Margaret; Katlama Christine; Moll Arend; Towner William; Trottier Benoit; Peeters Monika; Vingerhoets Johan; de Smedt Goedele; Baeten Benny; Beets Greet; Sinha Rekha; Woodfall Brian;
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet 2007;370(9581):39-48.
2007: Delaugerre Constance; Marcelin Anne-Genevieve; Soulié Cathia; Chaix Marie-Laure; Katlama Christine; Girard Pierre-Marie; Calvez Vincent; Morand-Joubert Laurence
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
AIDS (London, England) 2007;21(10):1365-7.
2007: Nelson Mark R; Katlama Christine; Montaner Julio S; Cooper David A; Gazzard Brian; Clotet Bonaventura; Lazzarin Adriano; Schewe Knud; Lange Joep; Wyatt Christina; Curtis Sue; Chen Shan-Shan; Smith Stephen; Bischofberger Norbert; Rooney James F
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Maigné Gwenola; Martinez Valérie; Thellier Marc; Bricaire François; Katlama Christine; Caumes Eric
Cryptosporidial diarrhoea in two HIV-infected patients: potential efficacy of rifampicin for successful treatment.
AIDS (London, England) 2007;21(9):1221-2.
2007: Ghosn J; Quinson A-M; Sabo Nd; Cotte L; Piketty C; Dorléacq N; Bravo M-L; Mayers D; Harmenberg J; Mårdh G; Valdez H; Katlama C
Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
HIV medicine 2007;8(3):142-7.
2007: Grinsztejn Beatriz; Nguyen Bach-Yen; Katlama Christine; Gatell Jose M; Lazzarin Adriano; Vittecoq Daniel; Gonzalez Charles J; Chen Joshua; Harvey Charlotte M; Isaacs Robin D;
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Lancet 2007;369(9569):1261-9.
2007: Clotet Bonaventura; Bellos Nicholas; Molina Jean-Michel; Cooper David; Goffard Jean-Christophe; Lazzarin Adriano; Wöhrmann Andrej; Katlama Christine; Wilkin Timothy; Haubrich Richard; Cohen Calvin; Farthing Charles; Jayaweera Dushyantha; Markowitz Martin; Ruane Peter; Spinosa-Guzman Sabrina; Lefebvre Eric;
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet 2007;369(9568):1169-78.
2007: Malet Isabelle; Wirden Marc; Derache Anne; Simon Anne; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
AIDS (London, England) 2007;21(7):871-3.
2007: Hill Andrew; Ruxrungtham Kiat; Hanvanich Mattana; Katlama Christine; Wolf Eva; Soriano Vincent; Milinkovic Ana; Gatell Jose; Ribera Esteban
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
Expert opinion on pharmacotherapy 2007;8(5):679-88.
2007: Malet Isabelle; Roquebert Bénédicte; Dalban Cécile; Wirden Marc; Amellal Bahia; Agher Rachid; Simon Anne; Katlama Christine; Costagliola Dominique; Calvez Vincent; Marcelin Anne-Geneviève
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
The Journal of infection 2007;54(4):367-74.
2007: Roquebert Bénédicte; Wirden Marc; Simon Anne; Deval Jérome; Katlama Christine; Calvez Vincent; Marcelin Anne-Geneviève
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
Journal of medical virology 2007;79(3):207-11.
2007: De Truchis Pierre; Kirstetter Myriam; Perier Antoine; Meunier Claire; Zucman David; Force Gilles; Doll Jacques; Katlama Christine; Rozenbaum Willy; Masson Hélène; Gardette Jean; Melchior Jean-Claude
Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.
Journal of acquired immune deficiency syndromes (1999) 2007;44(3):278-85.
2007: Katlama Christine; Esposito Roberto; Gatell Jose M; Goffard Jean-Christophe; Grinsztejn Beatriz; Pozniak Anton; Rockstroh Jurgen; Stoehr Albrecht; Vetter Norbert; Yeni Patrick; Parys Wim; Vangeneugden Tony;
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
AIDS (London, England) 2007;21(4):395-402.
2007: Dominguez Stephanie; Ghosn Jade; Peytavin Gilles; Izzedine Hassan; Wirden Marc; Ktorza Nadine; Miller Michael; Aubron-Olivier Camille; Trylesinski Aldo; Calvez Vincent; Deray Gilbert; Katlama Christine
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Journal of medical virology 2007;79(2):105-10.
2007: Derache Anne; Traore Ousmane; Koita Victoria; Sylla Aliou; Tubiana Roland; Simon Anne; Canestri Ana; Carcelain Guislaine; Katlama Christine; Calvez Vincent; Cisse Mamadou; Marcelin Anne-Geneviève
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
Antiviral therapy 2007;12(1):123-9.
2007: Marcelin Anne-Genevieve; Flandre Philippe; de Mendoza Carmen; Roquebert Benedicte; Peytavin Gilles; Valer Luisa; Wirden Marc; Abbas Sarah; Katlama Christine; Soriano Vincent; Calvez Vincent
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Antiviral therapy 2007;12(2):247-52.
2006: Schnuriger A; Dominguez S; Valantin M-A; Tubiana R; Duvivier C; Ghosn J; Simon A; Katlama C; Thibault V
[Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals]
Pathologie-biologie 2006;54(10):578-86.
2006: Katlama Christine; Ghosn Jade
Clinical trials for heavily pretreated patients: update in 2006.
Current opinion in HIV and AIDS 2006;1(6):495-501.
2006: Cahn Pedro; Villacian Jorge; Lazzarin Adriano; Katlama Christine; Grinsztejn Beatriz; Arasteh Keikawus; López Paulo; Clumeck Nathan; Gerstoft Jan; Stavrianeas Nikolas; Moreno Santiago; Antunes Francisco; Neubacher Dietmar; Mayers Douglas
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(10):1347-56.
2006: Eron Joseph; Yeni Patrick; Gathe Joseph; Estrada Vicente; DeJesus Edwin; Staszewski Schlomo; Lackey Philip; Katlama Christine; Young Benjamin; Yau Linda; Sutherland-Phillips Denise; Wannamaker Paul; Vavro Cindy; Patel Lisa; Yeo Jane; Shaefer Mark;
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Lancet 2006;368(9534):476-82.
2006: Hicks Charles B; Cahn Pedro; Cooper David A; Walmsley Sharon L; Katlama Christine; Clotet Bonaventura; Lazzarin Adriano; Johnson Margaret A; Neubacher Dietmar; Mayers Douglas; Valdez Hernan;
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet 2006;368(9534):466-75.
2006: Wirden Marc; Roquebert Bénédicte; Derache Anne; Simon Anne; Duvivier Claudine; Ghosn Jade; Dominguez Stephanie; Boutonnet Véronique; Ait-Arkoub Zaina; Katlama Christine; Calvez Vincent; Marcelin Anne-Genevieve
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.
Antimicrobial agents and chemotherapy 2006;50(7):2553-6.
2006: Avettand-Fenoel V; Thabut D; Katlama C; Poynard T; Thibault V
Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection.
Journal of clinical microbiology 2006;44(6):2250-3.
2006: Ouagari Zineb; Tubiana Roland; Mohand Hocine Ait; Dominguez Stephanie; Duvivier Claudine; Bricaire François; Katlama Christine; Caumes Eric
Skin rash associated with atazanavir: report of three cases.
AIDS (London, England) 2006;20(8):1207-8.
2006: Dominguez Stéphanie; Ghosn Jade; Valantin Marc-Antoine; Schruniger Aurélie; Simon Anne; Bonnard Philippe; Caumes Eric; Pialoux Gilles; Benhamou Yves; Thibault Vincent; Katlama Christine
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
AIDS (London, England) 2006;20(8):1157-61.
2006: Mocroft Amanda; Phillips Andrew N; Ledergerber Bruno; Katlama Christine; Chiesi Antonio; Goebel Frank-Detlef; Knysz Brygioa; Antunes Francisco; Reiss Peter; Lundgren Jens D
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
AIDS (London, England) 2006;20(8):1141-50.
2006: Schnuriger A; Dominguez S; Valantin M-A; Tubiana R; Duvivier C; Ghosn J; Simon A; Katlama C; Thibault V
Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals.
Journal of clinical microbiology 2006;44(4):1561-3.
2006: Astriti Myrto; Zeller Valérie; Boutolleau David; Gautheret-Dejean Agnès; Allen George; Seilhean Danielle; Agut Henri; Bricaire François; Katlama Christine; Bossi Philippe
Fatal HHV-6 associated encephalitis in an HIV-1 infected patient treated with cidofovir.
The Journal of infection 2006;52(4):237-42.
2006: Benhamou Yves; Fleury Herve; Trimoulet Pascale; Pellegrin Isabelle; Urbinelli Renaud; Katlama Christine; Rozenbaum Willy; Le Teuff Gwenael; Trylesinski Aldo; Piketty Christophe;
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Hepatology (Baltimore, Md.) 2006;43(3):548-55.
2006: Raffi Francois; Katlama Christine; Saag Michael; Wilkinson Martin; Chung Jain; Smiley Lynn; Salgo Miklos
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(6):870-7.
2006: Roquebert Bénédicte; Malet Isabelle; Wirden Marc; Tubiana Roland; Valantin Marc-Antoine; Simon Anne; Katlama Christine; Peytavin Gilles; Calvez Vincent; Marcelin Anne-Geneviève
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
AIDS (London, England) 2006;20(2):287-9.
2006: Spano Jean-Philippe; Carcelain Guislaine; Katlama Christine; Costagliola Dominique
[Non-AIDS-defining malignancies in HIV patients: clinical features and perspectives]
Bulletin du cancer 2006;93(1):37-42.
2006: Fox Zoe; Dragsted Ulrik B; Gerstoft Jan; Phillips Andrew N; Kjaer Jesper; Mathiesen Lars; Youle Mike; Katlama Christine; Hill Andrew; Bruun Johan N; Clumeck Nathan; Dellamonica Pierre; Lundgren Jens D;
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
Antiviral therapy 2006;11(6):761-70.
2006: Canestri Ana; Ghosn Jade; Wirden Marc; Marguet Françoise; Ktorza Nadine; Boubezari Imane; Dominguez Stéphanie; Bossi Philippe; Caumes Eric; Calvez Vincent; Katlama Christine
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Antiviral therapy 2006;11(5):561-6.
2006: Isnard Bagnis Corinne; Du Montcel Sophie Tezenas; Fonfrede Michele; Jaudon Marie Chantal; Thibault Vincent; Carcelain Guislaine; Valantin Marc Antoine; Izzedine Hassan; Servais Aude; Katlama Christine; Deray Gilbert
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era.
Nephron. Physiology 2006;103(3):p131-8.
2005: Nelson Mark; Arastéh Keikawus; Clotet Bonaventura; Cooper David A; Henry Keith; Katlama Christine; Lalezari Jacob P; Lazzarin Adriano; Montaner Julio S G; O'Hearn Mary; Piliero Peter J; Reynes Jacques; Trottier Benoit; Walmsley Sharon L; Cohen Calvin; Eron Joseph J; Kuritzkes Daniel R; Lange Joep; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Buss Neil E; Donatacci Lucille; Wat Cynthia; Smiley Lynn; Wilkinson Martin; Valentine Adeline; Guimaraes Denise; Demasi Ralph; Chung Jain; Salgo Miklos P
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Landman R; Descamps D; Peytavin G; Trylesinski A; Katlama C; Girard P M; Bonnet B; Yeni P; Bentata M; Michelet C; Benalycherif A; Brun Vezinet F; Miller M D; Flandre P;
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.
HIV clinical trials 2005;6(6):291-301.
2005: Katlama Christine
[HIV infection: now a chronic disease]
Presse médicale (Paris, France : 1983) 2005;34(20 Pt 2):1561-2.
2005: Boutboul François; Puthier Denis; Appay Victor; Pellé Olivier; Ait-Mohand Hocine; Combadière Béhazine; Carcelain Ghislaine; Katlama Christine; Rowland-Jones Sarah L; Debré Patrice; Nguyen Catherine; Autran Brigitte
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV.
AIDS (London, England) 2005;19(17):1981-6.
2005: Ghosn Jade; Duvivier Claudine; Tubiana Roland; Katlama Christine; Caumes Eric
Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(9):1360-1.
2005: Delaugerre Constance; Peytavin Gilles; Dominguez Stephanie; Marcelin Anne-Genevieve; Duvivier Claudine; Gourlain Karine; Amellal Bahia; Legrand Mayeule; Raffi François; Costagliola Dominique; Katlama Christine; Calvez Vincent
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Journal of medical virology 2005;77(3):345-50.
2005: Ghosn Jade; Wirden Marc; Ktorza Nadine; Peytavin Gilles; Aït-Mohand Hocine; Schneider Luminita; Dominguez Stéphanie; Bricaire François; Calvez Vincent; Costagliola Dominique; Katlama Christine
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
AIDS (London, England) 2005;19(15):1643-7.
2005: Agher R; Duvivier C; Katlama C; Gérard Y; Yazdanpanah Y; Billaud E; Jovelin T; Raffi F; Enel P; Poizot-Martin I; Puglièse P; Dellamonica P; Barone M; Cuzin L; Marchou B;
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals]
Médecine et maladies infectieuses 2005;35(7-8):407-10.
2005: Tubiana Roland; Carcelain Guislaine; Vray Muriel; Gourlain Karine; Dalban Cécile; Chermak Aziza; Rabian Claire; Vittecoq Daniel; Simon Anne; Bouvet Elisabeth; El Habib Raphaelle; Costagliola Dominique; Calvez Vincent; Autran Brigitte; Katlama Christine;
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
Vaccine 2005;23(34):4292-301.
2005: Wirden Marc; Marcelin Anne Genevieve; Simon Anne; Kirstetter Myriam; Tubiana Roland; Valantin Marc-Antoine; Paris Luc; Bonmarchand Manuela; Conan Francoise; Kalkias Laurence; Katlama Christine; Calvez Vincent
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Journal of medical virology 2005;76(3):297-301.
2005: Sacre Karim; Carcelain Guislaine; Cassoux Nathalie; Fillet Anne-Marie; Costagliola Dominique; Vittecoq Daniel; Salmon Dominique; Amoura Zahir; Katlama Christine; Autran Brigitte
Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease.
The Journal of experimental medicine 2005;201(12):1999-2010.
2005: Wirden Marc; Malet Isabelle; Derache Anne; Marcelin Anne Genevieve; Roquebert Benedicte; Simon Anne; Kirstetter Myriam; Joubert Laurence Morand; Katlama Christine; Calvez Vincent
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.
AIDS (London, England) 2005;19(6):630-2.
2005: Konopnicki Deborah; Mocroft Amanda; de Wit S; Antunes Francisco; Ledergerber Bruno; Katlama Christine; Zilmer K; Vella Stefano; Kirk Ole; Lundgren Jens D;
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS (London, England) 2005;19(6):593-601.
2005: Olsen Christian Holkmann; Gatell Jose; Ledergerber Bruno; Katlama Christine; Friis-Møller Nina; Weber Jonathan; Horban Andrzéj; Staszewski Schlomo; Lundgren Jens D; Phillips Andrew N;
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
AIDS (London, England) 2005;19(3):319-30.
2005: Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin A G; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
AIDS (London, England) 2005;19(1):25-33.
2005: Goujard Cécile; Legrand Mayeule; Panhard Xavière; Diquet Bertrand; Duval Xavier; Peytavin Gilles; Vincent Isabelle; Katlama Christine; Leport Catherine; Bonnet Bénédicte; Salmon-Céron Dominique; Mentré France; Taburet Anne-Marie;
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clinical pharmacokinetics 2005;44(12):1267-78.
2005: Mocroft Amanda; Rockstroh Jurgen; Soriano Vincent; Ledergerber Bruno; Kirk Ole; Vinogradova Elena; Reiss Peter; Katlama Christine; Phillips Andrew N; Lundgren Jens D;
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
Antiviral therapy 2005;10(7):779-90.
2005: Ghosn Jade; Guiguet Marguerite; Jardel Claude; Benyaou Rabah; Zeller Valérie; Simon Anne; Valantin Marc-Antoine; Amellal Bahia; Assoumo Lambert; Hogrel Jean-Yves; Costagliola Dominique; Katlama Christine; Lombès Anne
Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.
Antiviral therapy 2005;10(4):543-50.
2004: Marcelin Anne-Geneviève; Dalban Cécile; Peytavin Gilles; Lamotte Claire; Agher Rachid; Delaugerre Constance; Wirden Marc; Conan Françoise; Dantin Sylvie; Katlama Christine; Costagliola Dominique; Calvez Vincent
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2004;48(12):4687-92.
2004: van Leth Frank; Phanuphak Prahpan; Stroes Erik; Gazzard Brian; Cahn Pedro; Raffi François; Wood Robin; Bloch Mark; Katlama Christine; Kastelein John J P; Schechter Mauro; Murphy Robert L; Horban Andrzej; Hall David B; Lange Joep M A; Reiss Peter
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: Youle Mike; Cohen Cal; Katlama Christine; Kuritzkes Dan; Walmsley Sharon
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
Lancet 2004;364(9439):1036-7.
2004: Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David D-J; Simon A; Lamotte C; Marcelin A-G; Calvez V; Bricaire F; Costagliola D; Katlama C
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
HIV medicine 2004;5(5):352-9.
2004: Ghosn Jade; Chaix Marie-Laure; Peytavin Gilles; Rey Elisabeth; Bresson Jean-Louis; Goujard Cécile; Katlama Christine; Viard Jean-Paul; Tréluyer Jean-Marc; Rouzioux Christine
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
AIDS (London, England) 2004;18(14):1958-61.
2004: Marcelin Anne-Geneviève; Affolabi Dissou; Lamotte Claire; Mohand Hocine Ait; Delaugerre Constance; Wirden Marc; Voujon Delphine; Bossi Philippe; Ktorza Nadine; Bricaire François; Costagliola Dominique; Katlama Christine; Peytavin Gilles; Calvez Vincent
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Journal of medical virology 2004;74(1):16-20.
2004: Autran Brigitte; Costagliola Dominique; Murphy Robert; Katlama Christine
Evaluating therapeutic vaccines in patients infected with HIV.
Expert review of vaccines 2004;3(4 Suppl):S169-77.
2004: Katlama Christine
[AIDS research update]
Soins; la revue de référence infirmière 2004;(687):40.
2004: Torriani Francesca J; Rodriguez-Torres Maribel; Rockstroh Jürgen K; Lissen Eduardo; Gonzalez-García Juan; Lazzarin Adriano; Carosi Giampiero; Sasadeusz Joseph; Katlama Christine; Montaner Julio; Sette Hoel; Passe Sharon; De Pamphilis Jean; Duff Frank; Schrenk Uschi Marion; Dieterich Douglas T;
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
The New England journal of medicine 2004;351(5):438-50.
2004: Ghosn J; Pierre-François S; Thibault V; Duvivier C; Tubiana R; Simon A; Valantin M A; Dominguez S; Caumes E; Katlama C
Acute hepatitis C in HIV-infected men who have sex with men.
HIV medicine 2004;5(4):303-6.
2004: Yust I; Fox Z; Burke M; Johnson A; Turner D; Mocroft A; Katlama C; Ledergerber B; Reiss P; Kirk O;
Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2004;23(7):550-9.
2004: Wirden Marc; Marcelin Anne Geneviève; Tubiana Roland; Valantin Marc Antoine; Ghosn Jade; Duvivier Claudine; Dominguez Stéphanie; Paris Luc; Agher Rachid; Peytavin Gilles; Katlama Christine; Calvez Vincent
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Journal of acquired immune deficiency syndromes (1999) 2004;36(3):876-8.
2004: Marcelin Anne-Geneviève; Reynes Jacques; Yerly Sabine; Ktorza Nadine; Segondy Michel; Piot Jean-Claude; Delfraissy Jean-François; Kaiser Laurent; Perrin Luc; Katlama Christine; Calvez Vincent
Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.
AIDS (London, England) 2004;18(9):1340-2.
2004: Katlama Christine; Ghosn Jade; Tubiana Roland; Wirden Marc; Valantin Marc-Antoine; Harmenberg Johan; Mårdh Göran; Oberg Bo; Calvez Vincent
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.
AIDS (London, England) 2004;18(9):1299-304.
2004: Delaugerre Constance; Morand-Joubert Laurence; Chaix Marie-Laure; Picard Odile; Marcelin Anne-Genevieve; Schneider Veronique; Krivine Anne; Compagnucci Alexandra; Katlama Christine; Girard Pierre-Marie; Calvez Vincent
Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.
Antiviral therapy 2004;9(3):415-21.
2004: Lada Olivier; Benhamou Yves; Cahour Annie; Katlama Christine; Poynard Thierry; Thibault Vincent
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Antiviral therapy 2004;9(3):353-63.
2004: Valantin Marc-Antoine; Katlama Christine
[Why antiretroviral therapy must not begin to early?]
La Revue du praticien 2004;54(8):819-24.
2004: van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo U G; van der Westhuizen I P; Malan D R; Johnson M A; Santos B R; Mulcahy F; Wood R; Levi G C; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy R L; Horban A; Dam J P; Hassink E; van Leeuwen R; Robinson P; Wit F W; Lange J M A;
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Lancet 2004;363(9417):1253-63.
2004: d'Arminio Monforte Antonella; Cinque Paola; Mocroft Amanda; Goebel Frank-Detlev; Antunes Francisco; Katlama Christine; Justesen Ulrik Stenz; Vella Stefano; Kirk Ole; Lundgren Jens;
Changing incidence of central nervous system diseases in the EuroSIDA cohort.
Annals of neurology 2004;55(3):320-8.
2004: Ghosn Jade; Viard Jean-Paul; Katlama Christine; de Almeida Marta; Tubiana Roland; Letourneur Franck; Aaron Laurent; Goujard Cécile; Salmon Dominique; Leruez-Ville Marianne; Rouzioux Christine; Chaix Marie-Laure
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men.
AIDS (London, England) 2004;18(3):447-57.
2004: Wirden Marc; Delaugerre Constance; Marcelin Anne Genevieve; Ktorza Nadine; Ait Mohand Hocine; Dominguez Stephanie; Schneider Luminita; Ghosn Jade; Pauchard Michele; Costagliola Dominique; Katlama Christine; Calvez Vincent
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Antimicrobial agents and chemotherapy 2004;48(2):644-7.
2004: Alatrakchi Nadia; Di Martino Vincent; Thibault Vincent; Benhamou Yves; Katlama Christine; Poynard Thierry; Autran Brigitte
Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection.
AIDS (London, England) 2004;18(1):121-3.
2004: Katlama Christine; Dominguez Stéphanie; Gourlain Karine; Duvivier Claudine; Delaugerre Constance; Legrand Mayeule; Tubiana Roland; Reynes Jacques; Molina Jean-Michel; Peytavin Gilles; Calvez Vincent; Costagliola Dominique
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).
AIDS (London, England) 2004;18(2):217-26.
2004: Marcelin Anne-Geneviève; Delaugerre Constance; Wirden Marc; Viegas Pedro; Simon Anne; Katlama Christine; Calvez Vincent
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Journal of medical virology 2004;72(1):162-5.
2004: Spano Jean-Philippe; Massiani Marie-Ange; Bentata Michele; Rixe Olivier; Friard Sylvie; Bossi Philippe; Rouges François; Katlama Christine; Breau Jean-Luc; Morere Jean-Francois; Khayat David; Couderc Louis-Jean
Lung cancer in patients with HIV Infection and review of the literature.
Medical oncology (Northwood, London, England) 2004;21(2):109-15.
2003: Duvivier Claudine; Myrto Astriti; Marcelin Anne-Geneviève; Ghosn Jade; Ait-Mohand Hocine; Schneider Luminita; Agher Rachid; Bricaire François; Costagliola Dominique; Calvez Vincent; Peytavin Gilles; Katlama Christine
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Antiviral therapy 2003;8(6):603-9.
2003: Walmsley Sharon; Henry Keith; Katlama Christine; Nelson Mark; Castagna Antonella; Reynes Jacques; Clotet Bonaventura; Hui James; Salgo Miklos; DeMasi Ralph; Delehanty John
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
The Journal of infectious diseases 2003;188(12):1827-33.
2003: Valantin Marc-Antoine; Aubron-Olivier Camille; Ghosn Jade; Laglenne Elisabeth; Pauchard Michelle; Schoen Hélène; Bousquet Raymond; Katz Philippe; Costagliola Dominique; Katlama Christine
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
AIDS (London, England) 2003;17(17):2471-7.
2003: Hochedez P; Zeller V; Truffot C; Ansart S; Caumes E; Tubiana R; Katlama C; Bricaire F; Bossi P
[Lymph-node tuberculosis in patients infected or not with HIV: general characteristics, clinical presentation, microbiological diagnosis and treatment]
Pathologie-biologie 2003;51(8-9):496-502.
2003: Ghosn Jade; Paris Luc; Ajzenberg Daniel; Carcelain Guislaine; Dardé Marie-Laure; Tubiana Roland; Bossi Philippe; Bricaire François; Katlama Christine
Atypical toxoplasmic manifestation after discontinuation of maintenance therapy in a human immunodeficiency virus type 1-infected patient with immune recovery.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(7):e112-4.
2003: Caumes Eric; Bossi Philippe; Katlama Christine; Bricaire François
[Antiretroviral-induced toxiderma in HIV-infected patients]
Presse médicale (Paris, France : 1983) 2003;32(28):1325-33.
2003: Ghosn Jade; Brazille Patricia; Zeller Valérie; Stankoff Bruno; Katlama Christine; Bricaire François
[Tolosa-Hunt syndrome revealing Burkitt lymphoma in an HIV-seropositive patient]
Presse médicale (Paris, France : 1983) 2003;32(28):1319-22.
2003: Katlama C; Gazzard B; Mallolas J; Schürmann D; Moroni M; Demonty N; Antoun Z; Gordon D
Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
AIDS (London, England) 2003;17(12):1855-6.
2003: Mocroft Amanda; Ruiz Lidia; Reiss Peter; Ledergerber Bruno; Katlama Christine; Lazzarin Adriano; Goebel Frank-Detlef; Phillips Andrew N; Clotet Bonaventura; Lundgren Jens D;
Virological rebound after suppression on highly active antiretroviral therapy.
AIDS (London, England) 2003;17(12):1741-51.
2003: Gourlain K; Amellal B; Ait Arkoub Z; Dupin N; Katlama C; Calvez V
Quantitative analysis of human mitochondrial DNA using a real-time PCR assay.
HIV medicine 2003;4(3):287-92.
2003: Florence E; Lundgren J; Dreezen C; Fisher M; Kirk O; Blaxhult A; Panos G; Katlama C; Vella S; Phillips A;
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.
HIV medicine 2003;4(3):255-62.
2003: Mocroft A; Ledergerber B; Katlama C; Kirk O; Reiss P; d'Arminio Monforte A; Knysz B; Dietrich M; Phillips A N; Lundgren J D;
Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet 2003;362(9377):22-9.
2003: Katlama Christine
Time to scale up the fight against AIDS in Europe.
IAPAC monthly 2003;9(6):122.
2003: Delaugerre Constance; Gourlain Karine; Tubiana Roland; Carcelain Guislaine; Marcelin Anne-Geneviève; Chouquet Cécile; Mouroux Mireille; Duvivier Claudine; Autran Brigitte; Costagliola Dominique; Katlama Christine; Calvez Vincent
Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Antiviral therapy 2003;8(3):233-7.
2003: Katlama Christine
[Promising results with the anti-HIV vaccine]
Presse médicale (Paris, France : 1983) 2003;32(21):964.
2003: Zeller Valérie; Nardi Anne-Lyse; Truffot-Pernot Chantal; Sougakoff Wladimir; Stankoff Bruno; Katlama Christine; Bricaire François
Disseminated infection with a mycobacterium related to Mycobacterium triplex with central nervous system involvement associated with AIDS.
Journal of clinical microbiology 2003;41(6):2785-7.
2003: Wirden Marc; Simon Anne; Schneider Luminita; Tubiana Roland; Paris Luc; Marcelin Anne Genevieve; Delaugerre Constance; Legrand Mayeule; Herson Serge; Peytavin Gilles; Katlama Christine; Calvez Vincent
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Journal of clinical microbiology 2003;41(6):2713-5.
2003: Autran Brigitte; Debré Patrice; Walker Bruce; Katlama Christine
Therapeutic vaccines against HIV need international partnerships.
Nature reviews. Immunology 2003;3(6):503-8.
2003: Lazzarin Adriano; Clotet Bonaventura; Cooper David; Reynes Jacques; Arastéh Keikawus; Nelson Mark; Katlama Christine; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Lange Joep; Huson Les; DeMasi Ralph; Wat Cynthia; Delehanty John; Drobnes Claude; Salgo Miklos;
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
The New England journal of medicine 2003;348(22):2186-95.
2003: Thiébaut Rodolphe; Jacqmin-Gadda Hélène; Leport Catherine; Katlama Christine; Costagliola Dominique; Le Moing Vincent; Morlat Philippe; Chêne Geneviève;
Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures.
Journal of biopharmaceutical statistics 2003;13(2):271-82.
2003: Kousignian I; Autran B; Chouquet C; Calvez V; Gomard E; Katlama C; Rivière Y; Costagliola D;
Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients.
Statistics in medicine 2003;22(10):1675-90.
2003: Bossi Philippe; Peytavin Gilles; Lamotte Claire; Calvez Vincent; Bricaire François; Costagliola Dominique; Katlama Christine
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors.
AIDS (London, England) 2003;17(7):1108-10.
2003: van Leeuwen Remko; Katlama Christine; Murphy Robert L; Squires Kathleen; Gatell José; Horban Andrej; Clotet Bonaventura; Staszewski Shlomo; van Eeden Arne; Clumeck Nathan; Moroni Mauro; Pavia Andrew T; Schmidt Reinhold E; Gonzalez-Lahoz Juan; Montaner Julio; Antunes Francisco; Gulick Robert; Bánhegyi Dénes; van der Valk Marc; Reiss Peter; van Weert Liesbeth; van Leth Frank; Johnson Victoria A; Sommadossi Jean-Pierre; Lange Joep M
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2003: Cozzi-Lepri Alessandro; Phillips Andrew N; Miller Veronica; Katlama Christine; Ledergerber Bruno; Vella Stefano; Weber Jonathan; Bruun Johan N; Kirk Ole; Clotet Bonaventura; Lundgrens Jens D
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2003: Carcelain Guislaine; Saint-Mézard Pierre; Altes Hester Korthals; Tubiana Roland; Grenot Pierre; Rabian Claire; de Boer Rob; Costagliola Dominique; Katlama Christine; Debré Patrice; Autran Brigitte
IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia.
AIDS (London, England) 2003;17(6):841-50.
2003: Moore Antonia L; Kirk Ole; Johnson Anne M; Katlama Christine; Blaxhult Anders; Dietrich Manfred; Colebunders Robert; Chiesi Antonio; Lungren Jens D; Phillips Andrew N;
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):452-61.
2003: Mazeron Marie-Christine; Fillet Anne-Marie; Salmon Dominique; Boukli Narjis; Houhou Nadira; Sénéchal Brigitte; Matheron Sophie; Gozlan Joël; Leport Catherine; Katlama Christine; Scieux Catherine; Imbert Berthe-Marie; Deny Paul; Bour Jean-Baptiste; Freymuth François; Chanzy Bruno; Chaput Sophie; Costagliola Dominique;
Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy.
AIDS (London, England) 2003;17(5):784-6.
2003: Myers Robert P; Benhamou Yves; Imbert-Bismut Françoise; Thibault Vincent; Bochet Marie; Charlotte Frédéric; Ratziu Vlad; Bricaire François; Katlama Christine; Poynard Thierry
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
AIDS (London, England) 2003;17(5):721-5.
2003: Gourlain Karine; Salmon Dominique; Gault Elyanne; Leport Catherine; Katlama Christine; Matheron Sophie; Costagliola Dominique; Mazeron Marie-Christine; Fillet Anne-Marie;
Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
Journal of medical virology 2003;69(3):401-7.
2003: Marcelin Anne-Geneviève; Lamotte Claire; Delaugerre Constance; Ktorza Nadine; Ait Mohand Hocine; Cacace Raquel; Bonmarchand Manuela; Wirden Marc; Simon Anne; Bossi Philippe; Bricaire François; Costagliola Dominique; Katlama Christine; Peytavin Gilles; Calvez Vincent;
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2003;47(2):594-600.
2003: Ghosn Jade; Lamotte Claire; Ait-Mohand Hocine; Wirden Marc; Agher Rachid; Schneider Luminita; Bricaire François; Duvivier Claudine; Calvez Vincent; Peytavin Gilles; Katlama Christine
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
AIDS (London, England) 2003;17(2):209-14.
2003: Bossi P; Legrand O; Faussat A-M; Legrand M; Bricaire F; Marie J-P; Agut H; Diquet B; Katlama C; Huraux J-M; Calvez V
P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
HIV medicine 2003;4(1):67-71.
2003: Carrieri Patrizia; Spire Bruno; Duran Ségolène; Katlama Christine; Peyramond Dominique; François Cécile; Chêne Geneviève; Lang Jean-Marie; Moatti Jean-Paul; Leport Catherine;
Health-related quality of life after 1 year of highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2003;32(1):38-47.
2002: Chouquet Cécile; Autran Brigitte; Gomard Elisabeth; Bouley Jean-Marc; Calvez Vincent; Katlama Christine; Costagliola Dominique; Rivière Yves;
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection.
AIDS (London, England) 2002;16(18):2399-407.
2002: Katlama Christine; Carcelain Guislaine; Duvivier Claudine; Chouquet Cécile; Tubiana Roland; De Sa Marcio; Zagury Liliane; Calvez Vincent; Autran Brigitte; Costagliola D;
Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.
AIDS (London, England) 2002;16(15):2027-34.
2002: Calvez Vincent; Costagliola Dominique; Descamps Diane; Yvon Anne; Collin Gilles; Cécile Agnès; Delaugerre Constance; Damond Florence; Marcelin Anne-Geneviève; Matheron Sophie; Simon Anne; Valantin Marc-Antoine; Katlama Christine; Brun-Vézinet Françoise
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
Antiviral therapy 2002;7(3):211-8.
2002: Ait-Khaled Mounir; Stone Chris; Amphlett Gillian; Clotet Bonaventura; Staszewski Schlomo; Katlama Christine; Tisdale Margaret;
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
AIDS (London, England) 2002;16(12):1686-9.
2002: Delaugerre Constance; Marcelin Anne-Geneviève; Thibault Vincent; Peytavin Gilles; Bombled Tony; Bochet Marie-Valérie; Katlama Christine; Benhamou Yves; Calvez Vincent
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrobial agents and chemotherapy 2002;46(5):1586-8.
2002: Tubiana Roland; Ghosn Jade; De-Sa Marcio; Wirden Marc; Gautheret-Dejean Agnès; Bricaire François; Katlama Christine
Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission.
AIDS (London, England) 2002;16(7):1083-4.
2002: Soriano Vincent; Sulkowski Mark; Bergin Colm; Hatzakis Angelos; Cacoub Patrice; Katlama Christine; Cargnel Antonietta; Mauss Stefan; Dieterich Douglas; Moreno Santiago; Ferrari Carlo; Poynard Thierry; Rockstroh Jürgen
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.
AIDS (London, England) 2002;16(6):813-28.
2002: Sène D; Bossi Ph; Thomas L; Ghosn J; Zeller V; Caumes E; Katlama C; Bricaire F
[Legionellosis in HIV-1 infected patients. 4 case reports]
Presse médicale (Paris, France : 1983) 2002;31(8):356-8.
2002: Zeller Valérie; Truffot Chantal; Agher Rachid; Bossi Philippe; Tubiana Roland; Caumes Eric; Jouan Marc; Bricaire François; Katlama Christine
Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(5):662-7.
2002: Zeller V; Caumes E; Bossi P; Bricaire F; Katlama C
[Current clinical aspects of HIV/AIDS]
Presse médicale (Paris, France : 1983) 2002;31(2):74-9.
2002: Thibault Vincent; Delaugerre Constance; Calvez Vincent; Costagliola Dominique; Tubiana Roland; Katlama Christine
Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial.
Hepatology (Baltimore, Md.) 2002;35(1):238-9.
2002: Thibault Vincent; Aubron-Olivier Camille; Agut Henri; Katlama Christine
Primary infection with a lamivudine-resistant hepatitis B virus.
AIDS (London, England) 2002;16(1):131-3.
2002: Bossi Philippe; Paris Luc; Caumes Eric; Katlama Christine; Danis Martin; Bricaire François
Severe acute disseminated toxoplasmosis acquired by an immunocompetent patient in French Guiana.
Scandinavian journal of infectious diseases 2002;34(4):311-4.
2001: van der Valk M; Kastelein J J; Murphy R L; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato R K; Molhuizen H O; Reiss P;
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: Delaugerre C; Valantin M A; Mouroux M; Bonmarchand M; Carcelain G; Duvivier C; Tubiana R; Simon A; Bricaire F; Agut H; Autran B; Katlama C; Calvez V
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.
AIDS (London, England) 2001;15(16):2189-91.
2001: Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux J M; Katlama C; Calvez V
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Journal of medical virology 2001;65(3):445-8.
2001: Zeller V; Charlois C; Duvivier C; Bricaire F; Katlama C
Pseudo-primary infection syndrome following discontinuation of antiretroviral therapy.
Antiviral therapy 2001;6(3):191-3.
2001: Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin M A; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Antiviral therapy 2001;6(3):179-83.
2001: Rigolet A; Bossi P; Caumes E; Agher R; Zeller V; Katlama C; Bricaire F
[Epidemiological features and incidence trends of primary cerebral lymphomas observed in 80 HIV-infected patients from 1983 to 1999]
Pathologie-biologie 2001;49(7):572-5.
2001: Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet M H; Vig P; Gibbs C S; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Lancet 2001;358(9283):718-23.
2001: Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
Hepatology (Baltimore, Md.) 2001;34(2):283-7.
2001: Rollot F; Bossi P; Tubiana R; Caumes E; Zeller V; Katlama C; Bricaire F
Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy.
AIDS (London, England) 2001;15(11):1448-9.
2001: Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy J F; Trepo C; David F; Lanier E R; Vavro C; Mamet J P
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Antiviral therapy 2001;6(2):135-42.
2001: Delaugerre C; Mouroux M; Yvon-Groussin A; Simon A; Angleraud F; Huraux J M; Agut H; Katlama C; Calvez V
Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.
Antimicrobial agents and chemotherapy 2001;45(3):946-8.
2001: Baril L; Beucler I; Valantin M A; Bruckert E; Bonnefont-Rousselot D; Coutellier A; Caumes E; Katlama C; Bricaire F
Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy.
AIDS (London, England) 2001;15(3):415-7.
2001: Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
HIV medicine 2001;2(1):27-34.
2001: Katlama C; Pellegrin J L; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs J M; Delfraissy J F
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
HIV medicine 2001;2(1):20-6.
2001: Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet A M; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C;
Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.
AIDS (London, England) 2001;15(1):23-31.
2001: Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
Journal of virology 2001;75(1):234-41.
2000: Martinez V; Zeller V; Caumes E; Katlama C; Bricaire F
[Cutaneous vasculitis disclosing pulmonary tuberculosis]
Annales de médecine interne 2000;151(8):664-6.
2000: Combadère B; Blanc C; Li T; Carcelain G; Delaugerre C; Calvez V; Tubiana R; Debré P; Katlama C; Autran B
CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle.
European journal of immunology 2000;30(12):3598-603.
2000: Baril L; Jouan M; Agher R; Cambau E; Caumes E; Bricaire F; Katlama C
Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS.
AIDS (London, England) 2000;14(16):2593-6.
2000: Zylberberg H; Benhamou Y; Lagneaux J L; Landau A; Chaix M L; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Gut 2000;47(5):694-7.
2000: Samri A; Haas G; Duntze J; Bouley J M; Calvez V; Katlama C; Autran B
Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.
Journal of virology 2000;74(19):9306-12.
2000: Mollet L; Li T S; Samri A; Tournay C; Tubiana R; Calvez V; Debré P; Katlama C; Autran B
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(3):1692-704.
2000: Mocroft A; Katlama C; Johnson A M; Pradier C; Antunes F; Mulcahy F; Chiesi A; Phillips A N; Kirk O; Lundgren J D
AIDS across Europe, 1994-98: the EuroSIDA study.
Lancet 2000;356(9226):291-6.
2000: Mouroux M; Yvon-Groussin A; Peytavin G; Delaugerre C; Legrand M; Bossi P; Do B; Trylesinski A; Diquet B; Dohin E; Delfraissy J F; Katlama C; Calvez V
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.
Journal of clinical microbiology 2000;38(7):2726-30.
2000: Mocroft A; Miller V; Chiesi A; Blaxhult A; Katlama C; Clotet B; Barton S; Lundgren J D
Virological failure among patients on HAART from across Europe: results from the EuroSIDA study.
Antiviral therapy 2000;5(2):107-12.
2000: Mouroux M; Izopet J; Descamps D; Delaugerre C; Yvon-Groussin A; Angleraud F; Coutellier A; Bonmarchand M; Valantin M A; Matheron S; Agut H; Katlama C; Brun-Vezinet F; Calvez V
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]
Pathologie-biologie 2000;48(5):508-12.
2000: Salmon-Céron D; Mazeron M C; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet A M; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
AIDS (London, England) 2000;14(8):1041-9.
2000: Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
AIDS (London, England) 2000;14(7):781-9.
2000: Anduze-Faris B M; Fillet A M; Gozlan J; Lancar R; Boukli N; Gasnault J; Caumes E; Livartowsky J; Matheron S; Leport C; Salmon D; Costagliola D; Katlama C
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.
AIDS (London, England) 2000;14(5):517-24.
2000: Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
AIDS (London, England) 2000;14(2):163-71.
1999: Cassoux N; Bodaghi B; Katlama C; LeHoang P
CMV retinitis in the era of HAART.
Ocular immunology and inflammation 1999;7(3-4):231-5.
1999: Katlama C
[Managing HIV infection. 2 new aspects]
Presse médicale (Paris, France : 1983) 1999;28 Suppl 3():11-4.
1999: Chiesi A; Mocroft A; Dally L G; Miller V; Katlama C; Ledergerber B; Pedersen C; Phillips A N; Arcieri R; Lundgren J D
Regional survival differences across Europe in HIV-positive people: the EuroSIDA study.
AIDS (London, England) 1999;13(16):2281-8.
1999: Benhamou Y; Bochet M; Thibault V; Di Martino V; Caumes E; Bricaire F; Opolon P; Katlama C; Poynard T
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Hepatology (Baltimore, Md.) 1999;30(5):1302-6.
1999: Benhamou Y; Bochet M; Di Martino V; Charlotte F; Azria F; Coutellier A; Vidaud M; Bricaire F; Opolon P; Katlama C; Poynard T
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.
Hepatology (Baltimore, Md.) 1999;30(4):1054-8.
1999: Jouan M; Katlama C
Management of CMV retinitis in the era of highly active antiretroviral therapy.
International journal of antimicrobial agents 1999;13(1):1-7.
1999: Thibault V; Benhamou Y; Seguret C; Bochet M; Katlama C; Bricaire F; Opolon P; Poynard T; Agut H
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.
Journal of clinical microbiology 1999;37(9):3013-6.
1999: Bossi P; Mouroux M; Yvon A; Bricaire F; Agut H; Huraux J M; Katlama C; Calvez V
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor.
Journal of clinical microbiology 1999;37(9):2910-2.
1999: Katlama C
Review of NNRTIs: 'today and tomorrow'.
International journal of clinical practice. Supplement 1999;103():16-20.
1999: Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin M A; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux J M; Calvez V
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor]
Pathologie-biologie 1999;47(5):549-52.
1999: Neumann A U; Tubiana R; Calvez V; Robert C; Li T S; Agut H; Autran B; Katlama C
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
AIDS (London, England) 1999;13(6):677-83.
1999: Renaud M; Katlama C; Mallet A; Calvez V; Carcelain G; Tubiana R; Jouan M; Caumes E; Agut H; Bricaire F; Debré P; Autran B
Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen.
AIDS (London, England) 1999;13(6):669-76.
1999: Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos A I; Katzenstein T; van Lunzen J; Antunes F; Phillips A N; Lundgren J D
Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
Annals of internal medicine 1999;130(7):570-7.
1999: Autran B; Carcelaint G; Li T S; Gorochov G; Blanc C; Renaud M; Durali M; Mathez D; Calvez V; Leibowitch J; Katlama C; Debré P
Restoration of the immune system with anti-retroviral therapy.
Immunology letters 1999;66(1-3):207-11.
1999: Iborra C; Jouan M; Baril L; Katlama C; Bricaire F; Caumes E
High-dose trimethoprim-sulfamethoxazole therapy with corticosteroids in previously intolerant patients with AIDS-associated Pneumocystis carinii pneumonia.
Archives of dermatology 1999;135(3):350-1.
1999: Tubiana R; Carcelain G; Mohand H A; Li T S; Renaud M; Blanc C; Calvez V; Debré P; Agut H; Katlama C; Autran B; Bricaire F
[Immunologic reconstruction after antiretroviral treatment]
Presse médicale (Paris, France : 1983) 1999;28(8):424-8.
1999: Cassoux N; Lumbroso L; Bodaghi B; Zazoun L; Katlama C; LeHoang P
Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy.
The British journal of ophthalmology 1999;83(1):47-9.
1999: Carcelain G; Li T S; Renaud M; Blanc C; Tubiana R; Calvez V; Leibowitch J; Debré P; Agut H; Katlama C; Autran B
[Antiretroviral therapy and immune reconstitution]
Journal de la Société de biologie 1999;193(1):5-10.
1998: Breton G; Fillet A M; Katlama C; Bricaire F; Caumes E
Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(6):1525-7.
1998: Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell S M; Harrigan R P; Steel H; Lanier R E; Pearce G
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
AIDS (London, England) 1998;12(16):F197-202.
1998: Katlama C; Valantin M A; Matheron S; Coutellier A; Calvez V; Descamps D; Longuet C; Bonmarchand M; Tubiana R; De Sa M; Lancar R; Agut H; Brun-Vezinet F; Costagliola D
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.
Annals of internal medicine 1998;129(7):525-31.
1998: Haas G; Samri A; Gomard E; Hosmalin A; Duntze J; Bouley J M; Ihlenfeldt H G; Katlama C; Autran B
Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease.
AIDS (London, England) 1998;12(12):1427-36.
1998: Bossi P; Dupré S; Dupin N; Coutellier A; Bricaire F; Lubetzki C; Katlama C; Calvez V
[Clinical importance of the quantification of HIV-1 RNA in cerebrospinal fluid for the diagnosis of HIV encephalitis]
Pathologie-biologie 1998;46(6):423-5.
1998: Li T S; Tubiana R; Katlama C; Calvez V; Ait Mohand H; Autran B
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.
Lancet 1998;351(9117):1682-6.
1998: Bossi P; Caumes E; Astagneau P; Li T S; Paris L; Mengual X; Katlama C; Bricaire F
[Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994]
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 1998;19(5):313-7.
1998: Bossi P; Dupin N; Coutellier A; Bricaire F; Lubetzki C; Katlama C; Calvez V
The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(5):1072-3.
1998: Baril L; Astagneau P; Nguyen J; Similowski T; Mengual X; Beigelman C; Caumes E; Katlama C; Bricaire F
Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(4):964-71.
1998: Mollet L; Sadat-Sowti B; Duntze J; Leblond V; Bergeron F; Calvez V; Katlama C; Debré P; Autran B
CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity.
International immunology 1998;10(3):311-23.
1998: Martinez F; Mommeja-Marin H; Estepa-Maurice L; Beaufils H; Bochet M; Daudon M; Deray G; Katlama C
Indinavir crystal deposits associated with tubulointerstitial nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1998;13(3):750-3.
1997: Burke M; Yust I; Katlama C; Vardinon N; Clumeck N; Pinching A J; Ledergerber B; Gatell J M; Chiesi A; Barton S E; Lundgren J D; Pedersen C
Cytomegalovirus retinitis in patients with AIDS in Europe. AIDS in Europe Study Group.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997;16(12):876-82.
1997: Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin J P; Mills R; Rode R; Clementi M; Leibowitch J
Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Antiviral therapy 1997;2(3):175-83.
1997: Autran B; Carcelain G; Li T S; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Science (New York, N.Y.) 1997;277(5322):112-6.
1997: Katlama C
Management of CMV retinitis in HIV infected patients.
Genitourinary medicine 1997;73(3):169-73.
1997: Jouan M; Katlama C
[CMV infections in patients infected by HIV. Diagnosis, course, principles of treatment]
La Revue du praticien 1997;47(9):1017-22.
1997: Tubiana R; Gomard E; Fleury H; Gougeon M L; Mouthon B; Picolet H; Katlama C
Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
AIDS (London, England) 1997;11(6):819-20.
1997: Caumes E; Guermonprez G; Lecomte C; Katlama C; Bricaire F
Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus.
Archives of dermatology 1997;133(4):465-9.
1997: Hermans P; Lundgren J; Sommereijns B; Katlama C; Chiesi A; Goebel F D; Gonzales-Lahoz J; Proenza R; Barton S E; Pedersen C; Clumeck N
Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study Group.
AIDS (London, England) 1997;11(4):525-31.
1997: Staszewski S; Hill A M; Bartlett J; Eron J J; Katlama C; Johnson J; Sawyer W; McDade H
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
AIDS (London, England) 1997;11(4):477-83.
1996: Caumes E; Guermonprez G; Winter C; Katlama C; Bricaire F
A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(6):1313-4.
1996: Katlama C
Consequences for the management of cytomegalovirus.
AIDS (London, England) 1996;10 Suppl 1():S43-6.
1996: Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
Annals of internal medicine 1996;125(9):705-12.
1996: Katlama C; Mouthon B; Gourdon D; Lapierre D; Rousseau F
Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
AIDS (London, England) 1996;10(10):1107-12.
1996: Hermans P; Lundgren J; Sommereijns B; Pedersen C; Vella S; Katlama C; Lüthy R; Pinching A J; Gerstoft J; Pehrson P; Clumeck N
Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.
AIDS (London, England) 1996;10(8):911-7.
1996: Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill A M; Pearce G; McDade H
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
JAMA : the journal of the American Medical Association 1996;276(2):118-25.
1996: Leport C; Ambroise-Thomas P; Bazin C; Chène G; Derouin F; Katlama C; Mayaud C; Pelloux H; Raffi F; Vildé J L
[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February]
Presse médicale (Paris, France : 1983) 1996;25(11):519-20.
1996: Katlama C; De Wit S; O'Doherty E; Van Glabeke M; Clumeck N
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(2):268-75.
1996: Leport C; Ambroise-Thomas P; Bazin C; Chène G; Derouin F; Katlama C; Mayaud C; Pelloux H; Raffi F; Vildé J L
[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention]
Annales de médecine interne 1996;147(5):331-2.
1996: Katlama C; Havlir D V
Newer nucleosides: lamivudine and stavudine.
AIDS (London, England) 1996;10 Suppl A():S135-43.
1995: Caumes E; Bocquet H; Guermonprez G; Rogeaux O; Bricaire F; Katlama C; Gentilini M
Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(3):656-8.
1995: Blanshard C; Benhamou Y; Dohin E; Lernestedt J O; Gazzard B G; Katlama C
Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison.
The Journal of infectious diseases 1995;172(3):622-8.
1995: van Leeuwen R; Katlama C; Kitchen V; Boucher C A; Tubiana R; McBride M; Ingrand D; Weber J; Hill A; McDade H
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
The Journal of infectious diseases 1995;171(5):1166-71.
1995: Benhamou Y; Dohin E; Lunel-Fabiani F; Poynard T; Huraux J M; Katlama C; Opolon P; Gentilini M
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Lancet 1995;345(8946):396-7.
1993: Seilhean D; Duyckaerts C; Vazeux R; Bolgert F; Brunet P; Katlama C; Gentilini M; Hauw J J
HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex.
Neurology 1993;43(8):1492-9.
1993: Benhamou Y; Caumes E; Gerosa Y; Cadranel J F; Dohin E; Katlama C; Amouyal P; Canard J M; Azar N; Hoang C
AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients.
Digestive diseases and sciences 1993;38(6):1113-8.
1993: Caumes E; Gatineau M; Bricaire F; Dohin E; Katlama C; Gentilini M
Foscarnet-induced vulvar erosion.
Journal of the American Academy of Dermatology 1993;28(5 Pt 1):799.
1993: Hilmarsdottir I; Meynard J L; Rogeaux O; Guermonprez G; Datry A; Katlama C; Brücker G; Coutellier A; Danis M; Gentilini M
Disseminated Penicillium marneffei infection associated with human immunodeficiency virus: a report of two cases and a review of 35 published cases.
Journal of acquired immune deficiency syndromes 1993;6(5):466-71.
1992: Caumes E; Guermonprez G; Katlama C; Gentilini M
AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin.
AIDS (London, England) 1992;6(12):1483-7.
1992: Taburet A M; Katlama C; Blanshard C; Zorza G; Gazzard D; Dohin E; Gazzard B G; Frostegard C; Singlas E
Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Antimicrobial agents and chemotherapy 1992;36(9):1821-4.
1992: Cochereau-Massin I; LeHoang P; Lautier-Frau M; Zerdoun E; Zazoun L; Robinet M; Marcel P; Girard B; Katlama C; Leport C
Ocular toxoplasmosis in human immunodeficiency virus-infected patients.
American journal of ophthalmology 1992;114(2):130-5.
1992: Katlama C; Dohin E; Caumes E; Cochereau-Massin I; Brancon C; Robinet M; Rogeaux O; Dahan R; Gentilini M
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Journal of acquired immune deficiency syndromes 1992;5 Suppl 1():S18-24.
1991: Buffet R; Agut H; Chieze F; Katlama C; Bolgert F; Devillechabrolle A; Diquet B; Schuller E; Pierrot-Deseilligny C; Gentilini M
Virological markers in the cerebrospinal fluid from HIV-1-infected individuals.
AIDS (London, England) 1991;5(12):1419-24.
1991: Cochereau-Massin I; Lehoang P; Lautier-Frau M; Zazoun L; Marcel P; Robinet M; Matheron S; Katlama C; Gharakhanian S; Rozenbaum W
Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome.
Ophthalmology 1991;98(9):1348-53; discussion 1353-5.
1991: Katlama C
Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(3):189-91.
1991: Katlama C; Tubiana R; Rosenheim M; Valantin M A; Caumes E; Bricaire F; Gentilini M
Dideoxyinosine-associated hypokalaemia.
Lancet 1991;337(8734):183.
1990: Caumes E; Katlama C; Guermonprez G; Bournerias I; Danis M; Gentilini M
Cutaneous side-effects of bleomycin in AIDS patients with Kaposi's sarcoma.
Lancet 1990;336(8730):1593.
1990: Datry A; Similowski T; Jais P; Rosenheim M; Katlama C; Maheu E; Kazaz S; Fassin D; Danis M; Gentilini M
AIDS-associated leishmaniasis: an unusual gastro-duodenal presentation.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1990;84(2):239-40.
1989: Gentilini M; Katlama C
[Use of zidovudine during HIV infection]
Pathologie-biologie 1989;37(9):996.
1989: Lehoang P; Girard B; Robinet M; Marcel P; Zazoun L; Matheron S; Rozenbaum W; Katlama C; Morer I; Lernestedt J O
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Ophthalmology 1989;96(6):865-73; discussion 873-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Christine Katlama

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Christine Katlama (preview)

All Publications